Header
Sir Ganga Ram Hospital, New Delhi

How to Read Your Biopsy Report: A Plain Guide

Summary

A biopsy report (also called a pathology report) confirms what a tissue sample shows. It names the diagnosis, describes how abnormal the cells look (grade), and may include margins, lymph node findings, and biomarker results that guide treatment. It's written for doctors, so the language can feel cold and confusing, and a single word like "positive" can mean very different things depending on where it appears.

Reading it alongside your oncologist is the safest way to understand it. A biopsy report also isn't the whole story: stage usually needs imaging, and biomarker tests sometimes arrive in a separate report days later.

How to Read Your Biopsy Report: A Plain-Language Guide for Cancer Patients

How to Read Your Biopsy Report: A Plain-Language Guide for Cancer Patients

This page is for informational purposes only and does not replace medical advice. Please consult Dr Aditya Sarin or a qualified oncologist to interpret your own report. Reports vary between laboratories, so the terms below are general guides, not a diagnosis. As of 2026, this reflects current clinical guidance.

Many people get their biopsy report before they can sit with a doctor. You open the PDF, see words like “invasive ductal carcinoma, grade 2” or “margins focally involved,” and your mind races. That’s normal, and it’s why this guide exists. Here’s how to make sense of what’s on the page, without trying to diagnose yourself.

What is a biopsy report?

A biopsy removes a small piece of tissue or a sample of cells for a pathologist to study. A pathologist examines tissue under a microscope and writes the report. The National Cancer Institute describes a pathology report as a medical report that details the characteristics of a tissue specimen taken from a patient.

Types of biopsy

The kind of biopsy you had affects what the report can tell you. Some common procedures include:

  • Fine-needle aspiration (FNA): A thin needle draws out fluid and cells
  • Core needle biopsy: A larger needle removes a small column of tissue
  • Incisional biopsy: Part of a lump or area is removed
  • Excisional biopsy: The whole lump or suspicious area is removed
  • Endoscopic and bone marrow biopsies: Used for internal organs and for blood cancers

FNA gives the pathologist cells rather than intact tissue, so it can be less informative. A Komen breast biopsy guide notes that FNA can’t fully separate in situ cancer from invasive cancer, which is one reason a core biopsy is often done next.

How long do results take?

Routine results often come within a few days to a week, and special tests such as genetic or molecular testing may take one to three weeks. Timelines in Indian labs vary, so ask when to expect both the main report and any add-on tests. The wait is hard. It doesn’t mean something is wrong.

What’s in a biopsy report?

Formats differ between hospitals and labs, but the American Cancer Society says most reports follow a similar structure.

Patient and specimen details

The top of the report lists your details, the tissue site, the date, and how many samples were taken. Check that your name, age, and the body site are correct. A mix-up here matters.

Gross description

This describes what the pathologist saw with the naked eye: the tissue’s size, colour, and shape. It’s usually the least useful section for patients.

Microscopic description

This is where the real findings sit. The ACS says it usually covers the grade, how the cells are arranged, how far the cancer invades nearby tissue, whether cancer is at the edges of the sample, and lymph node status. Results of extra tests, such as special stains or biomarkers, may appear here or in a separate section.

Final diagnosis

This is the summary line, and the part most patients read first. For cancers, many reports include a structured checklist-style summary (a synoptic report) with tumour size, grade, margins, lymph nodes, and biomarkers. The NCI notes that this is where the cancer type, grade, lymph node status, margin status, and stage are identified.

Key terms in plain language

Benign, suspicious, atypical, malignant

Benign means not cancer. Malignant means cancer. Atypical or suspicious means the cells look abnormal, but the pathologist can’t call it cancer with certainty, so more sampling or surgery may follow. A biopsy doesn’t automatically mean cancer. Many results turn out to be noncancerous.

In situ vs invasive

In situ means abnormal cells are confined to where they started and haven’t grown into surrounding tissue. Invasive means the cells have grown beyond that layer. The distinction changes treatment, which is why it’s worth asking about if your report mentions either.

Grade: How abnormal the cells look

Grade describes how closely tumour cells resemble normal cells. As WebMD explains, grade 1 is low grade (well-differentiated), grade 2 is moderate, and grade 3 is high grade (poorly differentiated), with higher grades generally growing and spreading faster. Different cancers use different grading scales, so a “grade 2” in one cancer isn’t directly comparable to another.

Margins: Was it all removed?

If you had surgery, the report states whether cancer cells reach the edge of the removed tissue. The NCI describes negative (clean) margins as no cancer cells at the edge, suggesting all of the cancer was removed. Positive or involved margins mean cancer cells are at the edge, and your team may recommend more surgery or other treatment. Close margins mean cancer is near, but not at, the edge.

Lymph nodes: Positive or negative

Nodes are called positive if they contain cancer cells and negative if they don’t. The report may list how many nodes were examined and how many were affected. A positive node doesn’t automatically mean the worst, but it feeds into staging and treatment decisions.

Grade is not stage

This trips up a lot of people. Grade is what the cells look like under the microscope. Stage is how large the cancer is and how far it has spread. Staging often uses the TNM system, where T describes the tumour, N describes lymph nodes, and M describes spread to other parts of the body. A pathology report alone may not give a full stage, because staging usually combines the report with scans and other tests.

Biomarker results: ER, PR, HER2, PD-L1, Ki-67

Biomarker tests assess tumour features that guide treatment. For breast cancer, reports typically include hormone receptor (ER and PR) and HER2 status. The Canadian Breast Cancer Network adds that PD-L1 testing helps decide whether some people with triple-negative breast cancer could receive immunotherapy, and that Ki-67 reflects how quickly cells are dividing. Biomarker results may arrive in a separate or later report, so a first report that doesn’t list them isn’t necessarily incomplete.

This ties into treatment choices covered in our guide to cancer treatment options in India.

Common phrases decoded

What you read

In plain language

Benign

Not cancer

Malignant / carcinoma

Cancer

Atypical/suspicious

Abnormal cells, not clearly cancer; more testing may be needed

In situ

Cancer cells confined to where they began

Invasive

Cancer cells have grown into nearby tissue

Well differentiated (grade 1)

Cells look close to normal; usually slower growing

Poorly differentiated (grade 3)

Cells look very abnormal; usually faster growing

Margins negative/clear

No cancer at the edge of removed tissue

Margins positive/involved

Cancer reaches the edge; more treatment may be needed

Lymph nodes positive

Cancer cells found in a node

Lymph nodes negative

No cancer cells found in nodes examined

Addendum

Extra results added after the original report

Questions to ask your doctor

  • What exactly is my diagnosis, in plain words?
  • What are the grade and, if available, the stage? If staging isn’t complete, what tests are still needed?
  • Were biomarker or molecular tests done? When will the results come?
  • (If surgery was done) Are the margins clear, and are the lymph nodes involved?
  • Does this report change my treatment options?
  • Should the slides or tissue block be reviewed by another pathologist?

When to get a second opinion on your pathology

A cancer diagnosis shapes everything that follows, so it’s reasonable to confirm it, especially if the report is unclear, the diagnosis is rare, or the biopsy was done at a small lab. Hospitals in India routinely review slides from outside labs. 

What to send

  • The paraffin block, if possible. A block lets the reviewing lab cut new sections and run extra tests, which a finished slide can’t do, according to Acıbadem’s pathology guidance.
  • The slides and the original report.
  • Relevant scans. Context helps the reviewing pathologist.

Labs release blocks and slides on written request, and it’s an administrative step that can take a little time, so start early. Several centres offer this service.

Keep your tissue blocks and slides safe. They’re part of your medical record and can be needed again years later.

What a biopsy report can’t tell you

  • Your full stage: That needs imaging and sometimes more tests.
  • How your treatment will go: Grade and biomarkers inform decisions, but they don’t predict outcomes.
  • Everything at once: Reports can change. An addendum may add biomarker results or a revised interpretation, so ask whether any tests are still pending.

The takeaway

A biopsy report is the foundation of your treatment plan, and understanding it helps you take part in decisions instead of just receiving them. Read it once for the big picture, write down your questions, and review it with your oncologist rather than looking up each term on your own. If your diagnosis has just come through and you want a clear explanation, book a consultation with Dr Aditya Sarin to get a coordinated starting point. 

References

Frequently Asked Questions

Does a biopsy always mean I have cancer?

No. A biopsy is done to find out what’s causing a lump or abnormal finding, and many results are benign. It’s the only reliable way to confirm cancer, which is why it’s recommended.

What does “positive” mean on a biopsy report?

It depends on context. For margins, positive means cancer at the edge of the removed tissue. For lymph nodes, it means cancer cells were found. For a biomarker like ER, positive means the tumour has that receptor.

What is the difference between grade and stage?

Grade describes how abnormal the cells look under a microscope. Stage describes how big the cancer is and how far it has spread. They answer different questions.

How long do biopsy results take?

Often, a few days to a week, and special molecular tests can take 1 to 3 weeks. Ask your lab or doctor for a timeline for your specific tests.

Should I get a second opinion on my biopsy?

It’s reasonable, especially if the diagnosis is unclear or rare. A second pathologist reviews your original slides or tissue block, and many cancer centres in India offer this.

Can a pathology report change after it’s issued?

Yes. Additional results, such as biomarker tests, can be added as an addendum, and a report can be amended after further review.

Dr. Aditya Sarin — Medical Oncologist, Sir Ganga Ram Hospital, Delhi
Medically reviewed & written by

Dr. Aditya Sarin

Consultant, Medical Oncology · Sir Ganga Ram Hospital, New Delhi

MD (General Medicine) · DrNB (Medical Oncology) · ESMO (European) Board Certified

Dr. Aditya Sarin is a medical oncologist who combines precision molecular profiling with evidence-based, compassionate cancer care. Named Young Medical Oncologist of the Year, he treats the full spectrum of solid and blood cancers through a multidisciplinary tumor-board approach at Sir Ganga Ram Hospital.

Breast Cancer Lung Cancer GI Cancers Head & Neck Gynecologic Cancers Immunotherapy Targeted Therapy Precision / Molecular Oncology Leukemia · Lymphoma · Myeloma

Immunotherapy for Cancer: How It Works and Cost in India

Summary

Immunotherapy helps your own immune system recognise and attack cancer. The most common type, checkpoint inhibitors, blocks the signals that let cancer cells hide from immune cells. It works for some cancers and not others, usually depending on biomarker testing, and has side effects that differ from chemotherapy's because they come from an overactive immune system. In India, cost is the big question.

Pembrolizumab (Keytruda) remains very expensive and has no Indian biosimilar yet, while nivolumab has a much cheaper domestic biosimilar as of January 2026. Whether immunotherapy is right for you depends on your cancer, your tumour's biomarkers, and your overall plan, not on the price tag.

Immunotherapy for Cancer: How It Works, Who It Helps, and What It Costs in India

What immunotherapy actually does, how it differs from chemotherapy, and why the price picture is changing

This page is for informational purposes only and does not replace medical advice. Please consult Dr Aditya Sarin or a qualified oncologist about whether immunotherapy suits your diagnosis. Drug prices change quickly, so confirm current figures with your hospital. As of October 2026, this reflects current clinical guidance.

Immunotherapy is often called a breakthrough, and for the right patient, it is. But it also gets oversold, and the cost conversation in India can feel overwhelming. This guide covers how it works, how it compares with chemotherapy, who tends to benefit, what it costs right now, and practical safeguards worth knowing.

How does immunotherapy work?

Your immune system normally spots and destroys abnormal cells. Cancer survives by finding ways around that. The National Cancer Institute explains that immunotherapy helps your immune system fight cancer, and it’s a type of biological therapy, meaning a treatment made from substances produced by living organisms.

Checkpoint inhibitors

Your immune cells carry “checkpoint” proteins that act as brakes, so they don’t attack healthy tissue. Some cancers exploit this to switch off the immune response. Checkpoint inhibitors block that signal, releasing the brakes. Examples include pembrolizumab (Keytruda), nivolumab (Opdivo), atezolizumab, and durvalumab. These are among the most widely used immunotherapies.

Other types of immunotherapy

Checkpoint inhibitors aren’t the only kind. Others include:

  • CAR-T cell therapy, where a patient’s own T cells are modified in a lab to target cancer
  • Monoclonal antibodies that mark or block specific targets on cancer cells
  • Cancer vaccines, such as BCG for early-stage bladder cancer
  • Cytokines and other immune boosters used in a few cancers

For a closer look at how CAR-T fits into India’s options, see our guide to cancer treatment in India.

Immunotherapy vs chemotherapy

The two work in completely different ways. Chemotherapy kills fast-dividing cells throughout the body, which is why it also affects hair, gut lining, and blood counts. Immunotherapy doesn’t attack cancer cells directly. It mobilises your immune system to do that.

That difference shapes the side effects. Chemo tends to cause predictable side effects like nausea, hair loss, and low blood counts, while immunotherapy can cause the immune system to attack healthy tissue, leading to inflammation in the bowel, lungs, thyroid, liver, or skin. 

They’re also not rivals. Immunotherapy is often given alongside chemotherapy, and the right mix depends on the cancer.

Who does immunotherapy help?

Not everyone with cancer gets it, and not everyone who gets it responds. Eligibility depends mainly on your cancer type and what testing shows about your tumour.

Biomarker testing decides a lot

According to a summary from FORCE, some immunotherapies work best on cancers with certain biomarkers, such as defects in mismatch repair genes (dMMR or MSI-H), a high tumour mutational burden, or PD-L1 positivity. Testing your tumour before choosing immunotherapy helps avoid giving a costly treatment to someone unlikely to benefit.

Cancers where it’s commonly used

Dana-Farber lists cancers where checkpoint inhibitors have been approved in many forms, including Hodgkin lymphoma, urothelial cancers, and head and neck cancers, and notes that some cancers don’t respond to checkpoint inhibitors alone. CAR-T is approved for certain leukaemias, lymphomas, and, abroad, multiple myeloma.

It isn’t the answer for every cancer

For many cancers, including most head and neck cancers in India, surgery, radiation, and chemotherapy delivered on schedule remain the core of treatment. Immunotherapy is added when evidence and biomarkers support it. A good oncologist will tell you plainly when it isn’t the best next step.

What does immunotherapy cost in India?

This is where things are changing fastest. All figures below are indicative, drawn from published 2026 reports, and are not quotes. Prices vary by hospital, pharmacy, and dose, so ask for your exact cost in writing.

Nivolumab: A real price drop

Zydus Lifesciences launched a nivolumab biosimilar, Tishtha, in India in January 2026, priced at roughly a quarter of the reference drug, according to BioSpectrum. A cost comparison from CION Cancer Clinics illustrates the gap: roughly ₹1.5 to 2.8 lakh per cycle for the originator versus ₹35,000 to 70,000 for a biosimilar.

Pembrolizumab: still expensive

There’s no approved Indian biosimilar for pembrolizumab yet. Published figures put a 200 mg dose at roughly ₹3 to 4.2 lakh per cycle (CION), and the Indian patent is reported to run until around June 2028, so a cheaper version isn’t expected before about 2028 to 2029. Several manufacturers are reportedly working on one.

Drug

Indicative cost

Notes

Nivolumab (originator)

About ₹1.5 to 2.8 lakh per cycle

Indicative, 2026

Nivolumab (biosimilar)

About ₹35,000 to 70,000 per cycle

Tishtha launched Jan 2026; NIVORZ Sept 2026

Pembrolizumab

About ₹3 to 4.2 lakh per 3-weekly cycle

No Indian biosimilar yet

CAR-T (NexCAR19)

About ₹30 to 40 lakh

Specific blood cancers only

What drives your actual bill

The drug itself is only part of it. Your dose, how many cycles you need, whether vials are shared, the hospital, scans, and any admissions all change the total. Immunotherapy courses can run for many months, so ask for a full-course estimate, not just the first cycle.

Ways to make immunotherapy more affordable

  • Ask about biosimilars: If nivolumab is appropriate for you, a biosimilar can sharply cut the drug cost.
  • Ask about patient access programmes: Manufacturers have run programmes that reduce or waive drug costs after a set number of paid cycles. Availability changes, so ask your hospital pharmacy.
  • Check Ayushman Bharat PM-JAY: It covers up to ₹5 lakh per family per year, with cancer care under more than 200 packages, according to a Lok Sabha reply. Delhi joined the scheme in 2025 (BioSpectrum). Newer immunotherapy drugs may not be fully covered, so ask specifically about your drug.
  • Review your health insurance for cancer cover and drug sub-limits.

A safety point: Counterfeit cancer drugs

Reporting by The Indian Express and ICIJ, summarised by Vision IAS, found a counterfeit market for Keytruda in India, often in genuine-looking packaging. Buy only through your hospital’s pharmacy or an authorised supplier, keep the invoice and batch details, and be wary of unusually cheap offers from unofficial sources.

The takeaway

Immunotherapy can be a powerful option, but it’s a targeted one, matched to the cancer and its biomarkers rather than a general upgrade on chemotherapy. The cost picture is improving for nivolumab and may improve for pembrolizumab in a couple of years, so it’s worth asking an oncologist what’s available now. If you’ve been diagnosed and want to know whether immunotherapy fits your case, book a consultation with Dr Aditya Sarin for a clear, coordinated starting point.

References

Frequently Asked Questions

How is immunotherapy different from chemotherapy?

Chemotherapy kills fast-dividing cells directly, while immunotherapy helps your immune system attack cancer. Their side effects differ too: chemo’s tend to be predictable, while immunotherapy’s can involve inflammation in various organs.

Who is eligible for immunotherapy?

It depends on your cancer type, its stage, and biomarker results such as PD-L1, MSI-H or dMMR status, and tumour mutational burden. Your oncologist decides after testing.

How much does immunotherapy cost in India?

It varies a lot. A nivolumab biosimilar can cost roughly ₹35,000 to 70,000 per cycle, while pembrolizumab runs about ₹3 lakh or more per cycle. Ask your hospital for a written estimate of the full course.

Is there a cheaper version of Keytruda in India?

Not yet. As of the latest reports, no pembrolizumab biosimilar is approved in India, and its patent is reported to run until around 2028. A nivolumab biosimilar is available.

Does immunotherapy work for everyone?

No. Some cancers respond well, while others don’t, and responses vary even within the same cancer type. Biomarker testing helps predict who is more likely to benefit.

Is immunotherapy covered by Ayushman Bharat?

Cancer treatment is covered under PM-JAY up to ₹5 lakh per family per year, but coverage for specific newer drugs can be limited. Check your drug with the hospital.

Dr. Aditya Sarin — Medical Oncologist, Sir Ganga Ram Hospital, Delhi
Medically reviewed & written by

Dr. Aditya Sarin

Consultant, Medical Oncology · Sir Ganga Ram Hospital, New Delhi

MD (General Medicine) · DrNB (Medical Oncology) · ESMO (European) Board Certified

Dr. Aditya Sarin is a medical oncologist who combines precision molecular profiling with evidence-based, compassionate cancer care. Named Young Medical Oncologist of the Year, he treats the full spectrum of solid and blood cancers through a multidisciplinary tumor-board approach at Sir Ganga Ram Hospital.

Breast Cancer Lung Cancer GI Cancers Head & Neck Gynecologic Cancers Immunotherapy Targeted Therapy Precision / Molecular Oncology Leukemia · Lymphoma · Myeloma